Skip to main content
  1. Right Decisions
  2. Back
  3. Scottish referral guidelines for suspected cancer
  4. Upper gastrointestinal cancers

Urgent suspicion of cancer (USC) referral

Oesophago-gastric cancer:

Refer a person with any of the following to secondary care (follow local pathway) as a USC:

  • Persistent or progressive dysphagia (not ‘feeling of something stuck in the throat’ - FOSSIT)
  • Weight loss (5% or more of body weight or strong clinical suspicion) in a person aged 55 years or over with any of the following:
    • upper abdominal pain
    • early satiety
    • reflux
    • dyspepsia
    • nausea and/or vomiting

 

Hepato-pancreato-biliary cancer:

Refer a person with any of the following to secondary care (follow local pathway) as a USC:

  • Painless obstructive jaundice in a person aged 40 years or over
  • Weight loss (5% or more of body weight or strong clinical suspicion) in a person aged 55 years or over with any of the following:
    • change in bowel habit
    • back and/or abdominal pain
    • nausea and/or vomiting
    • new onset diabetes
  • Abdominal pain in a person aged 55 years or over with any of the following:
    • nausea and/or vomiting
    • weight loss (5% or more of body weight or strong clinical suspicion)
    • constipation
  • Palpable upper abdominal or epigastric mass
  • Any abnormality in the hepatobiliary tract/pancreas found on imaging that is suspicious for HPB cancer

 

Assessment for suspected upper GI cancers

Upper GI cancers often present with vague symptoms that are common complaints in primary care and, that on their own, have a low PPV for cancer75. The exceptions are dysphagia for oesophago-gastric cancer and jaundice for pancreatic cancer.

The clinical features of upper GI cancers overlap76.

Clinical feature OG cancer HPB cancer
Dysphagia  
Dyspepsia/reflux  
Nausea/vomiting
Upper abdominal pain
Early satiety (feeling full up after a small amount of food)
Abdominal mass
Unintentional weight loss
Jaundice  
Change in bowel habit  
New onset diabetes at older age - see USC referral  

 

The PPV for upper GI cancers can exceed 3% if there are combinations of symptoms:

  • Oesophago-gastric cancer16,77:
    • weight loss with abdominal pain, reflux or nausea/vomiting
  • Pancreatic cancer16
    • abdominal pain, with nausea/vomiting, constipation or weight loss

The PPVs are affected by age and this has been reflected in the referral criteria below.

If upper GI cancer is suspected:

  • Perform an abdominal examination
  • Arrange blood tests (full blood count to assess for anaemia and thrombocytosis, renal function, liver function tests and haemoglobin A1c)

Good practice points

Referral guidance:

Referral to secondary care for USC assessment will vary by Health Board – please follow the local pathway.

Referrals will be triaged by secondary care clinicians. It is therefore important that when a person is referred, they are advised they are being referred for assessment, not for a specific investigation (e.g. an endoscopy).

When making a referral for a person with dysphagia it is essential that the correct information is included in the referral form to allow the secondary care team to triage the referral. Please see CfSD’s Dysphagia pathway for guidance.

 

Overlap with other pathways:

Patients with intra-abdominal cancer can present with symptoms that overlap. Please see Lower GI cancer guideline, Ovarian cancer guideline and Kidney cancer guideline.

A normal Oesophago-Gastro-Duodenoscopy (OGD) or CT alone may be insufficient to exclude an upper GI cancer. Consideration should be given to using both modalities where clinically indicated, depending on symptoms, age, sex and risk factors.

There may also be a role for referral to a local pathway for non-specific symptoms in which cancer is suspected such as GP direct access to CT or to a RCDS. See also the Non-specific symptoms of cancer guideline.

Iron deficiency anaemia (IDA) falls below the 3% threshold for upper GI cancer and is therefore not included in the above USC referral criteria. See Lower gastrointestinal cancer guideline for initial investigation.

 

Thrombocytosis:

Evidence has identified thrombocytosis as a risk marker for malignancy17. In cases of unexplained thrombocytosis, it is advisable to assess for any signs or symptoms of cancer and if appropriate refer to a tumour specific USC pathway. Please see the section on thrombocytosis in Referral process/Further considerations for assessment and referral.

 

Background

Upper gastrointestinal (GI) cancer is an umbrella term for multiple different cancer types, including oesophageal, stomach, pancreatic, gallbladder and liver.

Upper GI cancers (excluding gallbladder due to data availability) accounted for around 9% of new cancer cases in Scotland in 2021 and 2022 (excluding non-melanoma skin cancer)1. Late stage diagnosis is common for upper GI cancers, with 25.0% of liver, 40.6% of stomach, 35.3% of oesophageal and 53.1% of pancreatic cancers being diagnosed at stage 4 in Scotland in 202129.Upper GI cancers (where incidence data is available in Scotland) have a higher incidence in those from more deprived areas4.

 

Oesophago-gastric (OG) cancer:

UK data (2017-2019) indicates the following risk factors70-72:

  • Increasing age (it is less likely under the age of 40)
  • Two times greater risk in men than women
  • Family history of OG cancer
  • Lower socioeconomic status
  • Smoking
  • Excessive alcohol use
  • Chronic gastro-oesophageal reflux
  • Barrett's oesophagus
  • Obesity (e.g. greater than two-fold higher risk of oesophageal cancer if BMI greater than 30 compared with Body Mass Index (BMI) less than 25)73
  • Prior history of aero-digestive cancers

 

Hepato-pancreato-biliary (HPB) cancer:

Pancreatic cancer is less likely below the age of 40 with incidence rates rising steeply from age 601. Risk factors include:

  • Smoking
  • Excessive alcohol use
  • Chronic pancreatitis
  • Family history

Liver cancer is less common than pancreatic cancer1. Risk factors include74:

  • Smoking
  • Obesity
  • Excessive alcohol use
  • Chronic liver disease
  • Viral hepatitis
  • Haemachromatosis
  • Family history of liver cancer